Polydex Pharmaceuticals Story

Polydex Pharmaceuticals Limited -- USA Stock  

USD 1.23  0.04  3.36%

Macroaxis News
  
By David Taylor

The industry average is where I look to next to determine where this stock should be in relation to they earnings potential.  This company is trading at 6.83 times earnings.  The industry and sector averages, respectively, are trading at 64.14 times and 63.11 times earnings.  This stock is trading at 1/10th the industry average despite positive earnings and increasing earnings growth.  

Given the EPS ratio, if the company were to be trading at .5 the industry average, 30-times EPS, the stock would be trading at $15.00 per share, a nearly 1,000 percent return.  Keep in mind that only gets the stock up to half the industry average.  

Polydex Pharma is trading at 110 the industry average offering a huge bargain with positive earnings

Polydex Pharma is trading at 1/10 the industry average offering a huge bargain with positive earnings.  Over the past many years earnings have been positive and increasing.  And, yet, the stock is trading at a single-digit EPS ratio.  Whereas the industry average is 65-times earnings, this pharmaceutical company is trading at 6-times earnings.  This is a tremendous opportunity.  




Polydex Pharmaceuticals is mostly a veterinary pharmaceutical company.  The develop, manufacture and distribute their products worldwide.  They are a smaller company with a market capitalization of only $6.2 million.  Their share price is $1.70 per share.  

The pet industry is a $15 billion per year sector.  Of that, there is a large percentage that goes towards health care from either veterinary visits and treatments.  Americans, and more increasingly the rest of the world, spend a considerable amount of money on their pets.  

Earnings-per-share gives a strong indication of what a company will be earning in the future, although this is not a certainty; it is only an indication.  If earnings-per-share are increasing over a given period, say five years, then the indication is that the company will continue to increase their earnings in the next year.  

In the case of POLXF, their earnings have been increasing over the latest few years, as this listing shows:

2012:  -$0.13  

2013:   $0.22  

2014:   $0.20  

2015:   $0.50 

The first thing you might see is that earnings for the previously complete year are on $0.50 in 2015.  Earnings are slated to rise above that for 2016.  But, how much does it cost to “earn” that next year’s earnings?  As mentioned above, only $1.70 per share.  Given all the variables, if the share price remained exactly the same while simultaneously the earnings remained the same, you would “earn” 29% for the year.  I am having a difficult time locating a better return on an annual basis than that.  That is an astronomically high earnings ratio.  

The industry average is where I look to next to determine where this stock should be in relation to they earnings potential.  POLXF is trading at 6.83 times earnings.  The industry and sector averages, respectively, are trading at 64.14 times and 63.11 times earnings.  This stock is trading at 1/10th the industry average despite positive earnings and increasing earnings growth.  

Given the EPS ratio, if the company were to be trading at 1/2 the industry average, 30-times EPS, the stock would be trading at $15.00 per share, a nearly 1,000 percent return.  Keep in mind that only gets the stock up to half the industry average.  

Another key variable that I find compelling about this company is its Inventory Turnover Ratio.  It leads the industry 3.79 versus 2.70.  It sells more of its inventory at a higher pace and a higher margin ratio.  This shows how effective management is at its job of returning value to investors.  And, yet, the stock is priced so low.  

Another point I wanted to show was the gross profit margin versus the industry.  POLXF earns slightly more than double the industry average, 22.8 percent versus 11.5 percent, respectively.  The company not only sells its inventory at a faster rate it also earns more in margins per sale.  

The economy itself is expanding throughout the world.  This will give POLXF the opportunity to expand its sales and continue to grow as a company.  The overall stock market is trading at 25 times earnings on average.  At some point, investors are going to start looking for increased value from earnings potential.  A company like POLXF is exactly that opportunity.  There is so much potential value in a stock priced so discounted to the industry and its own earnings.  

There are very few bargains in the market at this point. However, POLXF is far more than a bargain.  This is a bargain that is beyond difficult to pass.  Add this stock to your portfolio and hold this for a very long period.  You will be glad you did.  

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for Polydex Pharmaceuticals

over a week ago at http://nlrnews.com 
Shares of Polydex Pharmaceuticals Ltd. Moving Today
news
Investors have been buzzing over shares of Polydex Pharmaceuticals Ltd. as its price hit 1.12 at the end of the most recent trading day.
over two months ago at http://nlrnews.com 
Focusing the Lens on Polydex Pharmaceuticals Ltd.
news
Nelson ResearchFull coverage
over three months ago at http://www.whatech.com 
Discover the World dextran market insights to 2022
news
... and figures, product picture and specifications, sales, market share and contact information. Key Companies analyzed are Pharmacosmos, Dextran Products Limited, Polydex Pharmaceuticals Ltd, Meito Sangyo Co Ltd and Herbon International Holdings.
over six months ago at http://www.whatech.com 
Report explores the global dextran market
news
... valuable source of guidance and direction for companies and individuals interested in the market. Key Companies Analysis Pharmacosmos, Dextran Products Limited, Polydex Pharmaceuticals Ltd, Meito Sangyo Co Ltd and Herbon International Holdings.

Did you try this?

Run Balance Of Power Now
   

Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Hide  View All  NextLaunch Balance Of Power

Compare

Compare Polydex Pharmaceuticals To Peers

Debt to Equity

Debt to Equity Comparative Analysis
  Debt to Equity 
      Polydex Pharmaceuticals Comparables 
Polydex Pharmaceuticals is currently under evaluation in debt to equity category among related companies. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.